Specialized Studies

A Phase I unit intentionally designed to support early clinical development studies across a range of compounds. A collaborative model designed to give sponsors more certainty at the stage where it matters most.

Backed by experience from dozens of DDI trials, our team conducts inhibition and induction studies across all major CYP enzymes and transporter pathways.

Built for the precision these studies demand. Purpose-built cardiac infrastructure and the team continuity to ensure data quality from protocol startup to regulatory submission.

End-to-end clinical pharmacology support from study design and sampling strategy through clinical execution, analysis and reporting. Precise sample collection, barcode-enabled tracking, on-site processing and integrated scientific expertise help generate reliable data for dosing and development decisions.

The operational discipline food effect studies require. The attention to detail that protects data integrity.

Integrated teams, specialized infrastructure and direct access to experts from startup through study execution.

Integrated teams, specialized infrastructure and direct access to experts from startup through study execution.

Specialized expertise for the unique challenges these studies present. Access to the patient populations needed to keep programs moving forward.

Providing specialized clinical research services for Tobacco Harm Reduction programs, supporting sponsors from early protocol development through regulatory submission.